

Special Issue

The Omics Techniques in Obstetrical Pathologies

Message from the Guest Editor

Modern omics or Multi-Omics techniques, such as Genome, transcriptome, proteome and metabolome, are currently of great attention in the scientific, medical, and obstetrics/gynecological fields. The Omics Techniques study of the etiopathogenetic processes that underlie the development of obstetric or gynecological pathologies, such as pre-eclampsia, growth retardation, the threat of preterm birth, endometriosis, oncological pathology can lead to the identification of new therapeutic strategies. At the same time, the study of cellular, gene and transmission functions are also important. The aim of the special issue is to collect the latest research results of Omics Techniques application in obstetric diseases.

- genome
- transcriptome
- proteome
- metabolome
- Multi-Omics
- obstetric pathologies
- gynecological pathologies
- therapy

Guest Editor

Dr. Silvia Visentin

Gynecology and Obstetrics Unit, Department of Women's and Children's Health, University of Padua, Padua, Italy

Deadline for manuscript submissions

closed (31 March 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/86564

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).